libigrow RED DRAGON+ recall — Class I (D-0454-2024) · pharmaranks
Class IOngoing
libigrow RED DRAGON+ recall
FDA recall D-0454-2024 · initiated Mar 19, 2024
Most serious — a reasonable probability that use will cause serious harm or death.
Why it was recalled
Marketed without an approved NDA/ANDA: Products found to contain undeclared sildenafil and/or tadalafil.
Details
Product
libigrow RED DRAGON+, Maximum Strength Formula, 2 capsules per box, UPC 7 05105 83073 5.
Recalling company
Pyramids Wholesale Inc.
Classification
Class I
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
Mar 19, 2024
FDA report date
May 1, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.